| Year |
Citation |
Score |
| 2024 |
Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, ... ... Pinilla-Ibarz JA, et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discovery. PMID 38194367 DOI: 10.1158/2643-3230.BCD-23-0056 |
0.317 |
|
| 2023 |
Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, ... ... Pinilla-Ibarz J, et al. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. PMID 36727397 DOI: 10.3324/haematol.2022.281878 |
0.302 |
|
| 2022 |
Gamal W, Sahakian E, Pinilla-Ibarz J. The role of Th17 cells in chronic lymphocytic leukemia: friend or foe? Blood Advances. PMID 36574293 DOI: 10.1182/bloodadvances.2022008985 |
0.308 |
|
| 2021 |
Gaballa S, Pinilla-Ibarz J. BTK Inhibitors in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports. 16: 422-432. PMID 34599723 DOI: 10.1007/s11899-021-00645-1 |
0.313 |
|
| 2020 |
Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology. 11: 590072. PMID 33329575 DOI: 10.3389/fimmu.2020.590072 |
0.326 |
|
| 2020 |
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 21: 1188-1200. PMID 32888452 DOI: 10.1016/S1470-2045(20)30443-5 |
0.407 |
|
| 2020 |
Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Advances. 4: 4086-4090. PMID 32877523 DOI: 10.1182/Bloodadvances.2020002060 |
0.363 |
|
| 2020 |
Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4: 3268-3276. PMID 32702097 DOI: 10.1182/Bloodadvances.2020001900 |
0.399 |
|
| 2020 |
Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, ... Pinilla-Ibarz J, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances. 4: 3072-3084. PMID 32634240 DOI: 10.1182/Bloodadvances.2020001800 |
0.434 |
|
| 2020 |
Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, Pinilla-Ibarz J, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematology/Oncology and Stem Cell Therapy. PMID 32473105 DOI: 10.1016/J.Hemonc.2020.05.002 |
0.372 |
|
| 2020 |
Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Advances. 4: 2143-2157. PMID 32421811 DOI: 10.1182/Bloodadvances.2019001091 |
0.377 |
|
| 2020 |
Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, ... Pinilla-Ibarz J, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. PMID 32327504 DOI: 10.3324/Haematol.2019.238634 |
0.396 |
|
| 2020 |
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32198151 DOI: 10.1158/1078-0432.Ccr-19-3815 |
0.334 |
|
| 2020 |
Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Advances. 4: 530-538. PMID 32045474 DOI: 10.1182/Bloodadvances.2019000268 |
0.419 |
|
| 2020 |
Dong N, Saeed H, Gaballa S, Shah BD, Coghill A, Isenalumhe LL, Celeste B, Pinilla-Ibarz J, Chavez JC. Survival trend of chronic lymphocytic leukemia and prognostic factors in the United States: An analysis of the National Cancer Database. Journal of Clinical Oncology. 38: e20012-e20012. DOI: 10.1200/Jco.2020.38.15_Suppl.E20012 |
0.385 |
|
| 2020 |
Januzzi JL, Garasic J, Kasner S, McDonald V, Petrie MC, Seltzer J, Mauro MJ, Croce K, Berman E, Deininger MWN, Hochhaus A, Pinilla-Ibarz J, Nicolini FE, Kim D, DeAngelo DJ, et al. An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia. Journal of Clinical Oncology. 38: 7550-7550. DOI: 10.1200/Jco.2020.38.15_Suppl.7550 |
0.328 |
|
| 2020 |
Hashmi H, Mirza A, Darwin A, Logothetis C, Garcia F, Kommalapati A, Bachmeier CA, Benson K, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, et al. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.451 |
0.418 |
|
| 2020 |
Mirza A, Hashmi H, Darwin A, Garcia F, Kommalapati A, Logothetis C, Bachmeier CA, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, et al. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.431 |
0.415 |
|
| 2020 |
Hashmi H, Mirza A, Darwin A, Logothetis C, Garcia F, Kommalapati A, Bachmeier CA, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Jain MD, et al. Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.430 |
0.41 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, ... Pinilla-Ibarz J, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.399 |
|
| 2019 |
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, et al. Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports. 9: 14824. PMID 31597938 DOI: 10.1038/S41598-019-51403-6 |
0.302 |
|
| 2019 |
Zhang Y, Swoboda DM, Grover A, Nodzon L, Zhang L, Pinilla-Ibarz J. T315I-mutated myeloid sarcoma. Leukemia Research Reports. 12: 100184. PMID 31485411 DOI: 10.1016/J.Lrr.2019.100184 |
0.375 |
|
| 2019 |
Fradley MG, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, Armanious M, Lee DH, Walko C, Shah B, Chavez JC, McLeod H, Pinilla-Ibarz J, Schabath MB. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. The American Journal of Cardiology. PMID 31208701 DOI: 10.1016/J.Amjcard.2019.05.029 |
0.372 |
|
| 2019 |
Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Can increased immunogenicity in chronic myeloid leukemia improve outcomes? Expert Review of Hematology. 1-9. PMID 30855193 DOI: 10.1080/17474086.2019.1588105 |
0.433 |
|
| 2019 |
Logue JM, Krivenko GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E14019 |
0.401 |
|
| 2019 |
Dean E, Lu H, Lazaryan A, Krivenko GS, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma. Journal of Clinical Oncology. 37: 7562-7562. DOI: 10.1200/Jco.2019.37.15_Suppl.7562 |
0.368 |
|
| 2019 |
Knox TJ, Sahakian E, Banik D, Hadley M, Palmer E, Kim J, Noonepalle S, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee N, et al. Abstract LB-074: Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-074 |
0.346 |
|
| 2019 |
Maharaj K, Powers J, Achille A, Sahakian E, Pinilla-Ibarz J. Abstract 4723: Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia (CLL) Cancer Research. 79: 4723-4723. DOI: 10.1158/1538-7445.Am2019-4723 |
0.391 |
|
| 2019 |
Fischer K, Porro Lurà M, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati A, Pinilla-Ibarz J, Opat S, Sivcheva L, et al. FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES Hematological Oncology. 37: 82-84. DOI: 10.1002/Hon.52_2629 |
0.345 |
|
| 2018 |
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 30713125 DOI: 10.1016/J.Clml.2018.12.005 |
0.365 |
|
| 2018 |
Maharaj K, Powers JJ, Achille A, Deng S, Fonseca R, Pabon-Saldana M, Quayle SN, Jones SS, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances. 2: 3012-3024. PMID 30425065 DOI: 10.1182/Bloodadvances.2018020065 |
0.452 |
|
| 2018 |
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96. PMID 30340199 DOI: 10.1016/J.Leukres.2018.10.002 |
0.401 |
|
| 2018 |
Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. Future Oncology (London, England). PMID 30251548 DOI: 10.2217/Fon-2018-0371 |
0.344 |
|
| 2018 |
Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, et al. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. Bmc Cancer. 18: 359. PMID 29609532 DOI: 10.1186/S12885-018-4273-1 |
0.362 |
|
| 2018 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. PMID 29567798 DOI: 10.1182/Blood-2016-09-739086 |
0.4 |
|
| 2018 |
Kim DW, Saussele S, Williams LA, Mohamed H, Rong Y, Zyczynski T, Pinilla-Ibarz J, Abruzzese E. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Annals of Hematology. PMID 29556695 DOI: 10.1007/S00277-018-3295-8 |
0.384 |
|
| 2018 |
Yun S, Zhang L, Patel MR, Knepper TC, Chavez JC, Pinilla-Ibarz J. Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). Blood. PMID 29437555 DOI: 10.1182/Blood-2017-11-819276 |
0.374 |
|
| 2018 |
Koffman B, Dennison B, Kennard K, Byrd JC, Pagel JM, Davids MS, Nabhan C, Kay NE, Siddiqi T, Brander DM, Stephens DM, Hill BT, Pinilla-Ibarz J, Cheson BD, Rosen ST, et al. A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts). Journal of Clinical Oncology. 36: 7532-7532. DOI: 10.1200/Jco.2018.36.15_Suppl.7532 |
0.324 |
|
| 2018 |
Chen J, Cheng F, Sahakian E, Powers J, Wang Z, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition Cancer Research. 78: 4967-4967. DOI: 10.1158/1538-7445.Am2018-4967 |
0.379 |
|
| 2017 |
Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Advances. 1: 1867-1875. PMID 29296833 DOI: 10.1182/Bloodadvances.2017006809 |
0.442 |
|
| 2017 |
Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Current Opinion in Hematology. 25: 154-161. PMID 29266016 DOI: 10.1097/Moh.0000000000000403 |
0.366 |
|
| 2017 |
Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clinical Lymphoma, Myeloma & Leukemia. PMID 29126867 DOI: 10.1016/J.Clml.2017.10.002 |
0.348 |
|
| 2017 |
Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA. Using prognostic models in CLL to personalize approach to clinical care: Are we there yet? Blood Reviews. 32: 159-166. PMID 29122300 DOI: 10.1016/J.Blre.2017.10.003 |
0.303 |
|
| 2017 |
Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 29030092 DOI: 10.1016/J.Clml.2017.09.007 |
0.379 |
|
| 2017 |
Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J. Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-10. PMID 28641468 DOI: 10.1080/10428194.2017.1323271 |
0.355 |
|
| 2017 |
Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, ... ... Pinilla-Ibarz J, et al. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology. PMID 28550123 DOI: 10.1189/Jlb.1A0415-176Rrr |
0.321 |
|
| 2017 |
Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, et al. T-cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. PMID 28550044 DOI: 10.1182/Blood-2016-08-731505 |
0.376 |
|
| 2017 |
Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. PMID 28387926 DOI: 10.1002/Cncr.30558 |
0.37 |
|
| 2017 |
Talati C, Isenalumhe LL, Shams SR, Kuykendall AT, Chavez JC, Shah BD, Sweet KL, Pinilla-Ibarz J. Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era. Journal of Clinical Oncology. 35: e18546-e18546. DOI: 10.1200/Jco.2017.35.15_Suppl.E18546 |
0.392 |
|
| 2017 |
Kantarjian HM, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Santillana S, Guilhot F, Deininger MW, Hochhaus A, et al. Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). Journal of Clinical Oncology. 35: 7012-7012. DOI: 10.1200/Jco.2017.35.15_Suppl.7012 |
0.314 |
|
| 2017 |
Davids MS, Flinn IW, Mato AR, O'Connor OA, Brander DM, Lunning MA, Vose JM, Nastoupil L, Fowler N, Flowers C, Brown JR, Schreeder MT, Ghosh N, Lansigan F, Cheson BD, ... ... Pinilla-Ibarz J, et al. An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies Blood. 130: 4037-4037. DOI: 10.1182/Blood.V130.Suppl_1.4037.4037 |
0.344 |
|
| 2017 |
Ritchie EK, Catchatourian R, Klisovic RB, Pinilla-Ibarz J, Deininger MW, Erba HP, Radich JP, Savona MR, Dautaj I, Purkayastha D, Habucky K, Mauro MJ. Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib Blood. 130: 2875-2875. DOI: 10.1182/Blood.V130.Suppl_1.2875.2875 |
0.305 |
|
| 2017 |
Distler A, Brayer JB, Meads M, Sahakian E, Powers JJ, Alsina M, Nishihori T, Baz RC, Pinilla-Ibarz J, Sotomayor EM, Shain KH. HDAC11 as a candidate therapeutic target in multiple myeloma. Journal of Clinical Oncology. 35: 8029-8029. DOI: 10.1182/Blood.V130.Suppl_1.1800.1800 |
0.372 |
|
| 2017 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre PDl, Paquette R, Chuah C, Nicolini FE, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Mueller MC, Gambacorti-Passerini C, Castagnetti F, et al. Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study Blood. 130: 1617-1617. DOI: 10.1182/Blood.V130.Suppl_1.1617.1617 |
0.323 |
|
| 2017 |
Cortes JE, Kantarjian HM, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Talpaz M, Baccarani M, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Lustgarten S, Santillana S, et al. 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 17: S307-S308. DOI: 10.1016/J.Clml.2017.07.105 |
0.332 |
|
| 2016 |
Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clinical Lymphoma, Myeloma & Leukemia. PMID 28082112 DOI: 10.1016/J.Clml.2016.09.012 |
0.339 |
|
| 2016 |
Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. PMID 27927766 DOI: 10.3324/Haematol.2016.152710 |
0.386 |
|
| 2016 |
Sweet K, Pinilla-Ibarz J. NCCN and ELN: What do the guidelines tell us? Best Practice & Research. Clinical Haematology. 29: 264-270. PMID 27839567 DOI: 10.1016/J.Beha.2016.10.016 |
0.383 |
|
| 2016 |
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, ... ... Pinilla-Ibarz J, et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27660167 DOI: 10.1016/J.Bbmt.2016.09.013 |
0.401 |
|
| 2016 |
Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Oncotargets and Therapy. 9: 4937-57. PMID 27570458 DOI: 10.2147/Ott.S102504 |
0.398 |
|
| 2016 |
Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research. 47: 78-83. PMID 27285853 DOI: 10.1016/J.Leukres.2016.05.012 |
0.371 |
|
| 2016 |
Sweet K, Pinilla-Ibarz J. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Critical Reviews in Oncology/Hematology. PMID 27262540 DOI: 10.1016/J.Critrevonc.2016.05.009 |
0.424 |
|
| 2016 |
Emole J, Talabi T, Pinilla-Ibarz J. Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics : Targets & Therapy. 10: 23-31. PMID 27013862 DOI: 10.2147/Btt.S67844 |
0.414 |
|
| 2016 |
Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 26993758 DOI: 10.1016/J.Clml.2016.02.002 |
0.363 |
|
| 2016 |
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune Diseases and Myelodysplastic Syndromes. American Journal of Hematology. PMID 26875020 DOI: 10.1002/Ajh.24333 |
0.375 |
|
| 2016 |
Lienlaf M, Perez-Villarroel P, Knox T, Pabon M, Sahakian E, Powers J, Woan KV, Lee C, Cheng F, Deng S, Smalley KS, Montecino M, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Molecular Oncology. PMID 26775640 DOI: 10.1016/J.Molonc.2015.12.012 |
0.326 |
|
| 2016 |
Pinilla-Ibarz J, Emole J. Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. Cancer Control : Journal of the Moffitt Cancer Center. 22: 7-16. PMID 26618341 DOI: 10.1177/107327481502204S03 |
0.365 |
|
| 2016 |
Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clinical Lymphoma, Myeloma & Leukemia. S14-8. PMID 26297266 DOI: 10.1016/J.Clml.2015.03.013 |
0.426 |
|
| 2016 |
Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy. 7: 455-66. PMID 25917633 DOI: 10.2217/Imt.15.14 |
0.43 |
|
| 2016 |
Sandoval-Sus JD, Dalia S, Talati C, Shah BD, Bello CM, Lancet JE, Chervenick PA, Locke FL, Kharfan-Dabaja M, Sotomayor EM, Sokol L, Chavez JC, Pinilla-Ibarz J. Impact of IgVH mutational status in patients with chronic lymphocytic leukemia with isolated good and intermidiate risk genetic aberrations. Journal of Clinical Oncology. 34: 7534-7534. DOI: 10.1200/Jco.2016.34.15_Suppl.7534 |
0.382 |
|
| 2016 |
Cortes JE, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, et al. 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. Journal of Clinical Oncology. 34: 7013-7013. DOI: 10.1200/Jco.2016.34.15_Suppl.7013 |
0.349 |
|
| 2016 |
Sandoval-Sus JD, Stingo FE, Knepper TC, Nodzon L, Padron E, Kharfan-Dabaja MA, Chavez JC, Pinilla-Ibarz J. Mutational Landscape of Chronic Lymphocytic Leukemia Using Next Generation Sequencing Technologies in the Real World Clinical Setting Blood. 128: 4366-4366. DOI: 10.1182/Blood.V128.22.4366.4366 |
0.352 |
|
| 2016 |
Maharaj KK, Powers JJ, Pabon-Saldana M, Fonseca R, Achille A, Deng S, Miskin HP, Maryanski D, Sahakian E, Pinilla-Ibarz J. Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202 Blood. 128: 3236-3236. DOI: 10.1182/Blood.V128.22.3236.3236 |
0.423 |
|
| 2016 |
Ritchie EK, Catchatourian R, Klisovic RB, Pinilla-Ibarz J, Deininger MW, Erba HP, Radich JP, Savona MR, Dautaj I, Wolff J, Mauro MJ. ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib Blood. 128: 3090-3090. DOI: 10.1182/Blood.V128.22.3090.3090 |
0.329 |
|
| 2016 |
Maharaj KK, Powers JJ, Deng S, Achille A, Pabon-Saldana M, Fonseca R, Quayle SN, Jones SS, Sahakian E, Pinilla-Ibarz J. Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model Blood. 128: 2035-2035. DOI: 10.1182/Blood.V128.22.2035.2035 |
0.411 |
|
| 2016 |
Sweet KL, Hazlehurst L, Sahakian E, Powers JJ, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease Blood. 128: 1892-1892. DOI: 10.1182/Blood.V128.22.1892.1892 |
0.391 |
|
| 2016 |
Maharaj KK, Powers J, Fonseca R, Miskin H, Maryanski D, Sahakian E, Pinilla-Ibarz J. Abstract 545: Differential regulation of human T-cells by TGR-1202, a novel PI3Kδ inhibitor Cancer Research. 76: 545-545. DOI: 10.1158/1538-7445.Am2016-545 |
0.417 |
|
| 2016 |
Sweet K, Emole J, Mishra A, Pinilla-Ibarz J. Indications and Outcomes of Allogeneic Stem Cell Transplant for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors Clinical Lymphoma Myeloma and Leukemia. 16: S65-S66. DOI: 10.1016/J.Clml.2016.07.095 |
0.331 |
|
| 2016 |
Cortes J, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini F, Apperley J, Khoury HJ, Talpaz M, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, et al. 4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients Clinical Lymphoma Myeloma and Leukemia. 16: S56. DOI: 10.1016/J.Clml.2016.07.082 |
0.316 |
|
| 2015 |
Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KS, Bergman J, ... ... Pinilla-Ibarz J, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology. PMID 25957812 DOI: 10.1016/J.Molonc.2015.04.002 |
0.412 |
|
| 2015 |
Pinilla-Ibarz J, Chavez JC. Life after ibrutinib? A new unmet need in CLL Blood. 125: 2013-2014. PMID 25814485 DOI: 10.1182/Blood-2015-02-622472 |
0.313 |
|
| 2015 |
Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. American Journal of Hematology. 90: 602-7. PMID 25802083 DOI: 10.1002/Ajh.24014 |
0.325 |
|
| 2015 |
Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematologica. 133: 249-56. PMID 25413011 DOI: 10.1159/000365877 |
0.363 |
|
| 2015 |
Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology. 63: 579-85. PMID 25155994 DOI: 10.1016/J.Molimm.2014.08.002 |
0.332 |
|
| 2015 |
Cortes JE, Kim DG, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, et al. Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results. Journal of Clinical Oncology. 33: e18052-e18052. DOI: 10.1200/Jco.2015.33.15_Suppl.E18052 |
0.341 |
|
| 2015 |
Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, et al. Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study Blood. 126: 5142-5142. DOI: 10.1182/Blood.V126.23.5142.5142 |
0.335 |
|
| 2015 |
Nicolini FE, Basak GW, Kim D, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes TP, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Kageleiry A, Yang M, et al. The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation Blood. 126: 480-480. DOI: 10.1182/Blood.V126.23.480.480 |
0.383 |
|
| 2015 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, et al. Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial Blood. 126: 4025-4025. DOI: 10.1182/Blood.V126.23.4025.4025 |
0.36 |
|
| 2015 |
Sandoval-Sus JD, Chavez JC, Dalia S, Bello CM, Shah BD, Ho VQ, Nodzon L, Kharfan-Dabaja MA, Sotomayor EM, Sokol L, Pinilla-Ibarz J. Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience Blood. 126: 2945-2945. DOI: 10.1182/Blood.V126.23.2945.2945 |
0.433 |
|
| 2015 |
Kim D, Cleeland CS, Saussele S, Williams LA, Mohamed H, Pinilla-Ibarz J, Abruzzese E. Dasatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Persistent, Low-Grade Nonhematologic Toxicity to Imatinib: Results from Dasperse (CA180-400) Blood. 126: 1575-1575. DOI: 10.1182/Blood.V126.23.1575.1575 |
0.372 |
|
| 2015 |
Sandoval J, Corrales G, Rock-Klotz J, Pinilla-Ibarz J, Chavez J. Second Myeloid and Lymphoid Malignancies in patients with Chronic Lymphocytic Leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S207-S208. DOI: 10.1016/J.Clml.2015.04.070 |
0.406 |
|
| 2015 |
Chaudhury A, Rock-Klotz J, Teer J, Pinilla-Ibarz J, Chavez J. The Impact of NOTCH1 in the Prognosis of Chronic Lymphocytic Leukemia (CLL) Clinical Lymphoma Myeloma and Leukemia. 15: S205-S206. DOI: 10.1016/J.Clml.2015.04.067 |
0.403 |
|
| 2015 |
Gemmer J, Rock-Klotz J, Corrales-Yepez G, Pinilla-Ibarz J, Chavez J. Impact of the immunoglobulin heavy chain variable region mutational status in patients with low risk chronic lymphocytic leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S205. DOI: 10.1016/J.Clml.2015.04.066 |
0.344 |
|
| 2014 |
Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. International Journal of Hematology. 100: 567-74. PMID 25281405 DOI: 10.1007/S12185-014-1685-9 |
0.358 |
|
| 2014 |
Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. Journal of Immunology (Baltimore, Md. : 1950). 193: 2850-62. PMID 25108026 DOI: 10.4049/Jimmunol.1302778 |
0.366 |
|
| 2014 |
Sweet K, Pinilla-Ibarz J, Zhang L. Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Preference and Adherence. 8: 981-6. PMID 25045255 DOI: 10.2147/Ppa.S53160 |
0.38 |
|
| 2014 |
Chavez JC, Kharfan-Dabaja MA, Kim J, Yue B, Dalia S, Pinilla-Ibarz J, Anasetti C, Locke FL. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Leukemia Research. 38: 1165-72. PMID 24889511 DOI: 10.1016/J.Leukres.2014.04.006 |
0.391 |
|
| 2014 |
Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. The Journal of Clinical Investigation. 124: 2585-98. PMID 24812669 DOI: 10.1172/Jci73448 |
0.375 |
|
| 2014 |
Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Molecular Immunology. 60: 44-53. PMID 24747960 DOI: 10.1016/J.Molimm.2014.02.019 |
0.331 |
|
| 2014 |
Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leukemia & Lymphoma. 55: 2660-2. PMID 24528217 DOI: 10.3109/10428194.2014.894193 |
0.318 |
|
| 2014 |
Varker H, Song X, Meyer N, Gregory SA, Pinilla-Ibarz J, Ramsey SD. Treatment patterns, mortality, and costs of care in unfit patients (pts) with relapsed chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 32: 7105-7105. DOI: 10.1200/Jco.2014.32.15_Suppl.7105 |
0.32 |
|
| 2014 |
Xenakis A, Smith N, Beckerman R, Chhatwal J, Gregory SA, Pinilla-Ibarz J, Briggs A. A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia. Journal of Clinical Oncology. 32: 7101-7101. DOI: 10.1200/Jco.2014.32.15_Suppl.7101 |
0.374 |
|
| 2014 |
Kantarjian HM, Kim D, Pinilla-Ibarz J, Le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, Baccarani M, Lustgarten S, Haluska FG, Guilhot F, et al. Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. Journal of Clinical Oncology. 32: 7081-7081. DOI: 10.1200/Jco.2014.32.15_Suppl.7081 |
0.358 |
|
| 2014 |
Cheng F, Xia B, Sahakian E, Lwin T, Wang H, Xing L, Shah BD, PerezVillarroel P, LienlafMoreno M, Zhang Y, Quayle SN, Jones SS, Pinilla-Ibarz J, Villagra A, Sotomayor EM, et al. Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 124: 5397-5397. DOI: 10.1182/Blood.V124.21.5397.5397 |
0.388 |
|
| 2014 |
Brayer JB, Sahakian E, Powers J, Meads MB, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor EM, Shain KH. A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma Blood. 124: 4715-4715. DOI: 10.1182/Blood.V124.21.4715.4715 |
0.401 |
|
| 2014 |
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Lancet JE, Tinsley S, Nardelli LA, Benoit C, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes Blood. 124: 4653-4653. DOI: 10.1182/blood.V124.21.4653.4653 |
0.39 |
|
| 2014 |
Powers JJ, Maharaj KK, Sahakian E, Xing L, PerezVillarroel P, Knox T, Quayle S, Jones SS, Villagra A, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL) Blood. 124: 3311-3311. DOI: 10.1182/Blood.V124.21.3311.3311 |
0.419 |
|
| 2014 |
Chaudhury A, Chavez JC, Pinilla-Ibarz J. Utilization of Targeted Exome Sequencing to Determine Implications of TP53 Mutation Status in Relation to 17p Deletion in Chronic Lymphocytic Leukemia (CLL) Blood. 124: 3287-3287. DOI: 10.1182/Blood.V124.21.3287.3287 |
0.357 |
|
| 2014 |
Cortes JE, Kim D, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, et al. Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial Blood. 124: 3135-3135. DOI: 10.1182/Blood.V124.21.3135.3135 |
0.352 |
|
| 2014 |
Shah BD, Tao J, Chervenick PA, Riches ML, Pinilla-Ibarz J, Moscinski LC, Antonia S, Sotomayor EM, Dessureault S. Seven Year Followup for Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL) Blood. 124: 3083-3083. DOI: 10.1182/Blood.V124.21.3083.3083 |
0.366 |
|
| 2014 |
Wang H, Cheng F, Xing L, Zhao X, Villagra A, Pinilla-Ibarz J, Tao J. JQ 1, a Selective Bromodomain Inhibitor, Decreased the Expression of the Tolerogenic Molecule PDL1 in Antigen-Presenting Cells (APCs) and Restores the Responsiveness of Anergic CD4+ T Cells Blood. 124: 2749-2749. DOI: 10.1182/Blood.V124.21.2749.2749 |
0.416 |
|
| 2014 |
Chen J, Sahakian E, Powers JJ, LienlafMoreno M, Xing L, Deng S, Distler A, Cheng F, Villagra A, Horna P, Sotomayor EM, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition Blood. 124: 225-225. DOI: 10.1182/Blood.V124.21.225.225 |
0.326 |
|
| 2014 |
Sahakian E, Brayer J, Powers J, Meads M, Deng S, Distler A, Alsina M, Nishihori T, Baz R, Villagra A, Pinilla-Ibarz J, Sotomayor E, Shain K. Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma Cancer Research. 74: 5537-5537. DOI: 10.1158/1538-7445.Am2014-5537 |
0.387 |
|
| 2014 |
Woods DM, Sodre AL, Sahakian E, Powers J, Lienlaf-Moreno M, Perez-Villarroel P, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy Cancer Research. 74: 4090-4090. DOI: 10.1158/1538-7445.Am2014-4090 |
0.403 |
|
| 2014 |
Tang C, Ranatunga S, Kriss C, Cubitt C, Tao J, Pinilla-Ibarz J, Del Valle J, Hu C. 776: Inhibition of the IRE-1/XBP-1 pathway synergizes with ibrutinib for the treatment of B cell cancer European Journal of Cancer. 50: S186-S187. DOI: 10.1016/S0959-8049(14)50681-8 |
0.302 |
|
| 2013 |
O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, ... Pinilla-Ibarz J, et al. Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1327-40. PMID 24225967 DOI: 10.6004/Jnccn.2013.0157 |
0.387 |
|
| 2013 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 369: 1783-96. PMID 24180494 DOI: 10.1056/Nejmoa1306494 |
0.403 |
|
| 2013 |
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Critical Reviews in Oncology/Hematology. 88: 667-79. PMID 23969231 DOI: 10.1016/J.Critrevonc.2013.07.017 |
0.4 |
|
| 2013 |
Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. Journal of Hematology & Oncology. 6: 54. PMID 23870290 DOI: 10.1186/1756-8722-6-54 |
0.407 |
|
| 2013 |
Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evidence. 8: 37-45. PMID 23717217 DOI: 10.2147/Ce.S34068 |
0.456 |
|
| 2013 |
Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 1087-93. PMID 23632090 DOI: 10.1016/J.Bbmt.2013.04.020 |
0.358 |
|
| 2013 |
Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. American Journal of Hematology. 88: 566-70. PMID 23605934 DOI: 10.1002/Ajh.23454 |
0.355 |
|
| 2013 |
Brayer JB, Pinilla-Ibarz J. Developing strategies in the immunotherapy of leukemias. Cancer Control : Journal of the Moffitt Cancer Center. 20: 49-59. PMID 23302907 DOI: 10.1177/107327481302000108 |
0.328 |
|
| 2013 |
Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 21: 1097-103. PMID 23179489 DOI: 10.1007/S00520-012-1630-5 |
0.338 |
|
| 2013 |
Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 27: 907-13. PMID 23174881 DOI: 10.1038/Leu.2012.305 |
0.407 |
|
| 2013 |
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27: 107-12. PMID 22763385 DOI: 10.1038/Leu.2012.181 |
0.421 |
|
| 2013 |
Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, et al. Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial Blood. 122: 650-650. DOI: 10.1182/Blood.V122.21.650.650 |
0.352 |
|
| 2013 |
Dalia S, Brayer JB, Chavez JC, Bello CM, Shah BD, Horna P, Zhang H, Sokol L, Sotomayor EM, Pinilla-Ibarz J. Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia Blood. 122: 5290-5290. DOI: 10.1182/Blood.V122.21.5290.5290 |
0.396 |
|
| 2013 |
Chen J, Powers J, Rock-Klotz J, Deng S, Distler A, Cheng F, Villagra A, Sotomayor EM, Sahakian E, Pinilla-Ibarz J. Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β Blood. 122: 4887-4887. DOI: 10.1182/Blood.V122.21.4887.4887 |
0.314 |
|
| 2013 |
Zhang X, Sweet KL, Moscinski L, Hazlehurst LA, Pinilla-Ibarz J, Zhang L. Bone Marrow Beta-Catenin Expression In Chronic Myelogenous Leukemia Patients Treated With Imatinib Blood. 122: 2739-2739. DOI: 10.1182/Blood.V122.21.2739.2739 |
0.368 |
|
| 2013 |
Sahakian E, Powers J, Chen J, Distler A, Rock-Klotz J, Deng S, Wei S, Sotomayor EM, Pinilla-Ibarz J, Horna P. A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis Blood. 122: 2267-2267. DOI: 10.1182/Blood.V122.21.2267.2267 |
0.359 |
|
| 2013 |
Sahakian E, Brayer JB, Powers J, Meads M, Distler A, Deng S, Alsina M, Nishihori T, Baz R, Pinilla-Ibarz J, Sotomayor EM, Shain K. A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival Blood. 122: 1907-1907. DOI: 10.1182/Blood.V122.21.1907.1907 |
0.357 |
|
| 2013 |
Hochhaus A, Cortes JE, Kim D, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, et al. Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial Blood. 122: 1498-1498. DOI: 10.1182/Blood.V122.21.1498.1498 |
0.313 |
|
| 2013 |
Le Coutre PD, Kim D, Pinilla-Ibarz J, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, Dipersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, et al. Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) Blood. 122: 1496-1496. DOI: 10.1182/Blood.V122.21.1496.1496 |
0.329 |
|
| 2013 |
Lienlaf M, Perez-Villarroel P, Cheng F, Lee CK, Canales J, Knox T, Marante D, Yoder SJ, Woan KV, Pinilla-Ibarz J, Seto E, Sotomayor EM, Villagra A. Role Of Histone Deacetylase 6 (HDAC6) In The Modulation Of STAT Pathways and Immune Function Of APCs Blood. 122: 1032-1032. DOI: 10.1182/Blood.V122.21.1032.1032 |
0.347 |
|
| 2013 |
Woods DM, Woan K, Cheng F, Wang HW, Sahakian E, Powers J, Rock-Klotz J, Villagra A, Pinilla-Ibarz J, Sotomayor E. Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation. Cancer Research. 73: 692-692. DOI: 10.1158/1538-7445.Am2013-692 |
0.381 |
|
| 2012 |
Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619 |
0.432 |
|
| 2012 |
Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, Zanesi N, Epling-Burnette PK, Sotomayor EM, Croce CM, Del Valle JR, Hu CC. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 120: 1027-38. PMID 22692508 DOI: 10.1182/Blood-2011-11-394346 |
0.35 |
|
| 2012 |
Pinilla-Ibarz J, Flinn I. The expanding options for front-line treatment in patients with newly diagnosed CML. Critical Reviews in Oncology/Hematology. 84: 287-99. PMID 22487423 DOI: 10.1016/j.critrevonc.2012.03.005 |
0.326 |
|
| 2012 |
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leukemia Research. 36: 756-63. PMID 22209738 DOI: 10.1016/J.Leukres.2011.12.002 |
0.358 |
|
| 2012 |
Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 19: 54-67. PMID 22143062 DOI: 10.1177/107327481201900106 |
0.413 |
|
| 2012 |
Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 19: 37-53. PMID 22143061 DOI: 10.1177/107327481201900105 |
0.383 |
|
| 2012 |
Desai S, Pinilla-Ibarz J. Front-line therapy for chronic lymphocytic leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 19: 26-36. PMID 22143060 DOI: 10.1177/107327481201900104 |
0.399 |
|
| 2012 |
Apuri S, Lancet JE, Ali NHA, Padron E, Ho VQ, Pinilla-Ibarz J, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS) Blood. 120: 4937-4937. DOI: 10.1200/Jco.2013.31.15_Suppl.7113 |
0.388 |
|
| 2012 |
Domingo GC, Dalia S, Chavez JC, Carballido EM, Aguayo-Hiraldo PI, Sweet KL, Crescentini RM, Sokol L, Cultrera JL, Shah BD, Lancet JE, Sotomayor EM, Komrokji RS, Pinilla-Ibarz J. Impact of immunoglobulin heavy chain variable region mutational status on the outcome of patients with chronic lymphocytic leukemia harboring isolated 13q deletion. Journal of Clinical Oncology. 30: 6608-6608. DOI: 10.1200/Jco.2012.30.15_Suppl.6608 |
0.342 |
|
| 2012 |
Sweet KL, Komrokji RS, Ali NA, Crescentini RM, Domingo G, Chavez JC, Dalia S, Tinsley S, Lancet J, Zhang L, Pinilla-Ibarz J. Impact of ABL kinase domain mutations on the outcome of patients with chronic myeloid leukemia (CML). Journal of Clinical Oncology. 30: 6588-6588. DOI: 10.1200/Jco.2012.30.15_Suppl.6588 |
0.342 |
|
| 2012 |
Chavez JC, Domingo G, Dalia S, Dubovsky JA, Berchmans E, Powers JJ, Sweet KL, Crescentini RM, Sotomayor EM, Komrokji RS, Pinilla-Ibarz J. Cancer testicular antigens as a prognostic markers of chronic lymphocytic leukemia. Journal of Clinical Oncology. 30: 6575-6575. DOI: 10.1200/Jco.2012.30.15_Suppl.6575 |
0.672 |
|
| 2012 |
Dalia S, Chavez JC, Domingo G, Carballido EM, Aguayo-Hiraldo PI, Sweet KL, Crescentini RM, Sokol L, Bello CM, Cultrera JL, Shah BD, Lancet JE, Komrokji RS, Sotomayor EM, Pinilla-Ibarz J. Incidence of second and secondary malignancies in patients with CLL: A single institution experience. Journal of Clinical Oncology. 30: 6568-6568. DOI: 10.1200/Jco.2012.30.15_Suppl.6568 |
0.375 |
|
| 2012 |
Cortes JE, Kim D, Pinilla-Ibarz J, Paquette R, Coutre PDl, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Rea D, Abruzzese E, Muller MC, et al. PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Journal of Clinical Oncology. 30: 6503-6503. DOI: 10.1200/Jco.2012.30.15_Suppl.6503 |
0.312 |
|
| 2012 |
Kantarjian HM, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial Blood. 120: 915-915. DOI: 10.1182/Blood.V120.21.915.915 |
0.345 |
|
| 2012 |
Woods DM, Woan KV, Sahakian E, Powers J, Cheng F, Wang H, Rock-Klotz J, Weber JS, Villagra A, Pinilla-Ibarz J, Sotomayor EM. Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype Blood. 120: 840-840. DOI: 10.1182/Blood.V120.21.840.840 |
0.387 |
|
| 2012 |
Sahakian E, Powers J, Horna P, Rock-Klotz J, Deng S, Woods DM, Nguyen M, Woan KV, Cheng F, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis Blood. 120: 4728-4728. DOI: 10.1182/Blood.V120.21.4728.4728 |
0.355 |
|
| 2012 |
Komrokji RS, Ali NHA, Mishra A, Corrales-Yepez M, Padron E, Zhang L, Epling-Burnette PK, Little BJ, Pinilla-Ibarz J, Lancet JE, List AF. The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities Blood. 120: 3852-3852. DOI: 10.1182/Blood.V120.21.3852.3852 |
0.351 |
|
| 2012 |
Powers J, Sahakian E, Dubovsky JA, Farnum T, Berchmans E, McNeel DG, Skikne BS, MacBeth KJ, Komrokji RS, Pinilla-Ibarz J. Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine Blood. 120: 3828-3828. DOI: 10.1182/Blood.V120.21.3828.3828 |
0.664 |
|
| 2012 |
Komrokji RS, Corrales-Yepez M, Al Ali NH, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF. Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes Blood. 120: 3826-3826. DOI: 10.1182/Blood.V120.21.3826.3826 |
0.352 |
|
| 2012 |
Cortes JE, Lipton JH, Miller CB, Ailawadhi S, Akard L, Pinilla-Ibarz J, Lin FP, Ericson SG, Mauro MJ. Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL) Blood. 120: 3782-3782. DOI: 10.1182/Blood.V120.21.3782.3782 |
0.303 |
|
| 2012 |
Hochhaus A, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, et al. Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial Blood. 120: 3763-3763. DOI: 10.1182/Blood.V120.21.3763.3763 |
0.389 |
|
| 2012 |
Kim D, Cortes JE, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial Blood. 120: 3749-3749. DOI: 10.1182/Blood.V120.21.3749.3749 |
0.404 |
|
| 2012 |
Mauro MJ, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, et al. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial Blood. 120: 3747-3747. DOI: 10.1182/Blood.V120.21.3747.3747 |
0.368 |
|
| 2012 |
Sweet KL, Al Ali NH, Lancet JE, Creelan B, Tinsley S, Shah BD, Zhang L, Komrokji RS, Pinilla-Ibarz J. Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy Blood. 120: 3740-3740. DOI: 10.1182/Blood.V120.21.3740.3740 |
0.436 |
|
| 2012 |
Wang H, Cheng F, Wang Z, Lienlaf M, Perez-Villarroel P, Knox T, Sahakian E, Pinilla-Ibarz J, Horna P, Chen-Kiang S, Martin P, Bergman J, Kozikowski A, Villagra A, Tao J, et al. Inhibition of Histone Deacetylase 6 (HDAC6) Disrupts the Tolerogenic STAT3 Signaling Pathway and Augments Antitumor Immune Responses in Mantle Cell Lymphoma (MCL) Blood. 120: 3724-3724. DOI: 10.1182/Blood.V120.21.3724.3724 |
0.434 |
|
| 2012 |
Mishra A, Ali NHA, Corrales-Yepez M, Padron E, Zhang L, Epling-Burnette PK, Kharfan-Dabaja MA, Pinilla-Ibarz J, Little BJ, Lancet JE, List AF, Komrokji RS. Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications. Blood. 120: 2816-2816. DOI: 10.1182/Blood.V120.21.2816.2816 |
0.313 |
|
| 2012 |
Mishra A, Lancet JE, Ali NHA, Padron E, Ho VQ, Little BJ, Pinilla-Ibarz J, List AF, Komrokji RS. Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure. Blood. 120: 2815-2815. DOI: 10.1182/Blood.V120.21.2815.2815 |
0.377 |
|
| 2012 |
Sweet KL, Ali NHA, Komrokji RS, Lancet JE, Pinilla-Ibarz J. Macrocytosis and Iron Stores in Patients with Chronic Myeloid Leukemia Being Treated with Tyrosine Kinase Inhibitors. Blood. 120: 2769-2769. DOI: 10.1182/Blood.V120.21.2769.2769 |
0.316 |
|
| 2012 |
Chavez J, Kim J, Dalia S, Kharfan-Dabaja MA, Pinilla-Ibarz J, Anasetti C, Locke FL. Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Blood. 120: 2007-2007. DOI: 10.1182/Blood.V120.21.2007.2007 |
0.336 |
|
| 2012 |
Sahakian E, Rock-Klotz J, Shah BD, Powers J, Cultrera JL, Deng S, Woods DM, Nguyen M, Cheng F, Wang H, Perez-Villarroel P, Lienlaf M, Knox T, Chen-Kiang S, Villagra A, ... ... Pinilla-Ibarz J, et al. Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL) Blood. 120: 1660-1660. DOI: 10.1182/Blood.V120.21.1660.1660 |
0.403 |
|
| 2012 |
Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial Blood. 120: 163-163. DOI: 10.1182/Blood.V120.21.163.163 |
0.385 |
|
| 2012 |
Lienlaf M, Perez-Villarroel P, Cheng F, Wang H, Marante D, Yoder S, V. WK, Knox T, Lagor S, Pinilla-Ibarz J, Seto E, Sotomayor EM, Villagra A. Critical Role for Histone Deacetylase 6 (HDAC6) in the Regulation of IL-6, and the JAK/STA3 Signaling Cascade in Macrophages Blood. 120: 1039-1039. DOI: 10.1182/Blood.V120.21.1039.1039 |
0.344 |
|
| 2012 |
Woan KV, Vazquez L, Rock-Klotz J, Wang Z, Cheng F, Wang H, Woods D, Sahakian E, Perez P, Lienlaf M, Achille A, Bergman J, Kalin J, Gill A, Powers J, ... ... Pinilla-Ibarz J, et al. Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma Cancer Research. 72: 3555-3555. DOI: 10.1158/1538-7445.Am2012-3555 |
0.42 |
|
| 2012 |
Woods DM, Woan KV, Wang H, Cheng F, Wang Z, Vazquez L, Perez P, Lienlaf M, Rock-Klotz J, Sahakian E, Powers J, Deng S, Oscar M, Atadja P, Seto E, ... Pinilla-Ibarz J, et al. Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progressionin vivo Cancer Research. 72: 3554-3554. DOI: 10.1158/1538-7445.Am2012-3554 |
0.39 |
|
| 2011 |
Cortes JE, Miller CB, Lipton JH, Busque L, Akard LP, Pinilla-Ibarz J, Ericson S, Mauro MJ. Open-label study evaluating change in chronic low-grade (LG) non-hematologic (heme) adverse events (AEs) in Philadelphia positive (Ph+) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6615. PMID 28020256 DOI: 10.1200/Jco.2011.29.15_Suppl.6615 |
0.31 |
|
| 2011 |
Veliz M, Pinilla-Ibarz J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. Journal of Blood Medicine. 2: 71-7. PMID 22287865 DOI: 10.2147/Jbm.S13063 |
0.367 |
|
| 2011 |
Bello C, Veliz M, Pinilla-Ibarz J. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Expert Review of Clinical Immunology. 7: 295-300. PMID 21595596 DOI: 10.1586/Eci.11.15 |
0.371 |
|
| 2011 |
Cortes JE, Hochhaus A, Le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib Blood. 117: 5600-5606. PMID 21467546 DOI: 10.1182/Blood-2010-11-318949 |
0.417 |
|
| 2011 |
Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. Leukemia Research. 35: 1193-9. PMID 21377729 DOI: 10.1016/J.Leukres.2011.02.007 |
0.684 |
|
| 2011 |
Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. Journal of Immunology (Baltimore, Md. : 1950). 186: 3986-96. PMID 21368229 DOI: 10.4049/Jimmunol.1001101 |
0.368 |
|
| 2011 |
O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-25. PMID 21335443 DOI: 10.6004/Jnccn.2011.0125 |
0.415 |
|
| 2011 |
Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma. 52: 668-79. PMID 21271862 DOI: 10.3109/10428194.2010.550074 |
0.707 |
|
| 2011 |
Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leukemia Research. 35: 301-4. PMID 21109304 DOI: 10.1016/J.Leukres.2010.09.002 |
0.323 |
|
| 2011 |
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 117: 1141-5. PMID 21098399 DOI: 10.1182/Blood-2010-03-277152 |
0.43 |
|
| 2011 |
Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leukemia Research. 35: 394-404. PMID 20863567 DOI: 10.1182/Blood.V114.22.5116.5116 |
0.703 |
|
| 2011 |
Castro JE, Schwartzberg LS, Pinilla-Ibarz J, Kipps TJ, Cantwell MJ. A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 29: 6528-6528. DOI: 10.1200/Jco.2011.29.15_Suppl.6528 |
0.365 |
|
| 2011 |
Pinilla-Ibarz J, Navaie M, Smith JC, Beaubrun AC, McCullough LE, Hickey AH, Toseland RW. What's Missing in Chronic Myeloid Leukemia Research: The Paucity of Studies Linking Health-Related Quality of Life to Adverse Events From the Perspectives of Patients, Physicians and Family Caregivers Blood. 118: 4758-4758. DOI: 10.1182/Blood.V118.21.4758.4758 |
0.376 |
|
| 2011 |
Pound HB, Ho VQ, Bello CM, Cultrera JL, Extermann M, Lancet JE, Sotomayor EM, Pinilla-Ibarz J. Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience Blood. 118: 4620-4620. DOI: 10.1182/Blood.V118.21.4620.4620 |
0.398 |
|
| 2011 |
Teichman ML, Ho VQ, Balducci L, Bello CM, Pinilla-Ibarz J. Efficacy of Ofatumumab and High-Dose Methylprednisolone for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 118: 4619-4619. DOI: 10.1182/Blood.V118.21.4619.4619 |
0.439 |
|
| 2011 |
Jacobsen P, Sweet KL, Lee Y, Tinsley S, Lancet JE, Komrokji RS, Cabrera P, Pinilla-Ibarz J. Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia (CML) Blood. 118: 4431-4431. DOI: 10.1182/Blood.V118.21.4431.4431 |
0.396 |
|
| 2011 |
Lipton JH, Mauro MJ, Ailawadhi S, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Ericson SG, Shah J, Cortes JE. Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events Blood. 118: 4422-4422. DOI: 10.1182/Blood.V118.21.4422.4422 |
0.33 |
|
| 2011 |
Shah BD, Zhang L, Bulkeley W, Moscinski L, Papenhausen P, Pinilla-Ibarz J. Outcome of Complex Variant Philadelphia Positive Chromosome Translocations in the Era of Tyrosine Kinase Inhibitors, Blood. 118: 3788-3788. DOI: 10.1182/Blood.V118.21.3788.3788 |
0.433 |
|
| 2011 |
le Coutre PD, Giles FJ, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D, Branford S, Müller MC, Shou Y, et al. Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study, Blood. 118: 3770-3770. DOI: 10.1182/Blood.V118.21.3770.3770 |
0.311 |
|
| 2011 |
Shah BD, Tao J, Sokol L, Chervenick PA, Tomblyn M, Pinilla-Ibarz J, Moscinski L, Antonia S, Sotomayor EM, Dessureault S. Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL), Blood. 118: 3720-3720. DOI: 10.1182/Blood.V118.21.3720.3720 |
0.378 |
|
| 2011 |
Kharfan-Dabaja MA, Anasetti C, Luis N, Brand L, Perkins J, Fernandez HF, Ochoa-Bayona JL, Nishihori T, Perez LE, Ayala E, Pinilla-Ibarz J, Sokol L, Pidala J, Locke FL, Sotomayor EM, et al. Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression Blood. 118: 3022-3022. DOI: 10.1182/Blood.V118.21.3022.3022 |
0.353 |
|
| 2011 |
Komrokji RS, Pinilla-Ibarz J, Yu D, Nardelli L, Cubitt C, Zhao X, Fernandez HF, List AF, Lancet JE. A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia Blood. 118: 2604-2604. DOI: 10.1182/Blood.V118.21.2604.2604 |
0.448 |
|
| 2011 |
Sahakian E, Powers J, Rock-Klotz J, Adriani M, Woan KV, Merino O, Gill AS, Deng S, Cheng F, Villagra A, Luetteke N, Seto E, Sotomayor EM, Borrello IM, Pinilla-Ibarz J. A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion Blood. 118: 2439-2439. DOI: 10.1182/Blood.V118.21.2439.2439 |
0.348 |
|
| 2011 |
Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, ... ... Pinilla-Ibarz J, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725 |
0.668 |
|
| 2011 |
Castro JE, Schwartzberg L, Pinilla-Ibarz J, Melo-Cardenas J, Barajas-Gamboa JS, Cantwell MJ, Kipps TJ. Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) Induces Complete and Partial Responses In a Phase 1b Study for Patients with Fludarabine-Refractory and/or Del(17p)/p53-Defective Chronic Lymphocytic Leukemia (CLL) Blood. 118: 168-168. DOI: 10.1182/Blood.V118.21.168.168 |
0.391 |
|
| 2011 |
Sahakian E, Shah BD, Powers J, Deng S, Merino O, Gill AS, Rock-Klotz J, Woan KV, Vazquez L, Wang H, Chen-Kiang S, Tao J, Villagra A, Pinilla-Ibarz J, Sotomayor EM. The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) Blood. 118: 1363-1363. DOI: 10.1182/Blood.V118.21.1363.1363 |
0.404 |
|
| 2011 |
Cortes JE, Kim D, Pinilla-Ibarz J, Coutre PDL, Chuah C, Nicolini FE, Paquette R, Apperley JF, DiPersio JF, Khoury HJ, Rea D, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, et al. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation Blood. 118: 109-109. DOI: 10.1182/Blood.V118.21.109.109 |
0.335 |
|
| 2011 |
Dubovsky JA, Powers JJ, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz JA. Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2’-deoxycytidine Cancer Research. 71: 5526-5526. DOI: 10.1158/1538-7445.Am2011-5526 |
0.685 |
|
| 2011 |
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Abstract 5033: Stromal-derived conditioned media activates STAT3 via JAK2 and TYK2 and results inde novoresistance to Nilotinib Cancer Research. 71: 5033-5033. DOI: 10.1158/1538-7445.Am2011-5033 |
0.378 |
|
| 2010 |
Hartley MA, Sokol L, Caceres G, Hussein MA, List A, Pinilla-Ibarz J. Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. Mediterranean Journal of Hematology and Infectious Diseases. 2: e2010002. PMID 21415944 DOI: 10.4084/Mjhid.2010.002 |
0.322 |
|
| 2010 |
Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 117: 688-97. PMID 20922786 DOI: 10.1002/Cncr.25648 |
0.412 |
|
| 2010 |
Pinilla-Ibarz J, McQuary A. Chronic lymphocytic leukemia: putting new treatment options into perspective. Cancer Control : Journal of the Moffitt Cancer Center. 17: 4-15; quiz 16. PMID 20404796 DOI: 10.1177/1073274810017002S03 |
0.422 |
|
| 2010 |
Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 116: 171-9. PMID 20400682 DOI: 10.1182/Blood-2009-10-250993 |
0.399 |
|
| 2010 |
Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunology Letters. 131: 126-30. PMID 20346983 DOI: 10.1016/J.Imlet.2010.03.004 |
0.367 |
|
| 2010 |
Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer. 116: 2665-72. PMID 20310049 DOI: 10.1002/Cncr.25079 |
0.338 |
|
| 2010 |
Dubovsky JA, Villagra A, Powers JJ, Wang HW, Pinilla-Ibarz J, Sotomayor EM. Circumventing immune tolerance through epigenetic modification. Current Pharmaceutical Design. 16: 268-76. PMID 20109136 DOI: 10.2174/138161210790170120 |
0.644 |
|
| 2010 |
Shah BD, Tao J, Sokol L, Chervenick PA, Tomblyn MR, Pinilla-Ibarz J, Moscinski L, Antonia S, Sotomayor EM, Dessureault S. Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results. Journal of Clinical Oncology. 28: 2608-2608. DOI: 10.1200/Jco.2010.28.15_Suppl.2608 |
0.368 |
|
| 2010 |
Dubovsky JA, Powers J, Gao Y, Mariusso LF, Sotomayor EM, Pinilla-Ibarz J. Molecular, Epigenetic, and Phenotypic Repolarization of T Lymphocytes From Chronic Lymphocytic Leukemia Patients Using 5-Aza-2′-Deoxycytidine Blood. 116: 4651-4651. DOI: 10.1182/Blood.V116.21.4651.4651 |
0.681 |
|
| 2010 |
Veliz M, Powers J, Zhang L, Santana E, Lancet JE, Komrokji RS, Kharfan-Dabaja M, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J. Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL Blood. 116: 4630-4630. DOI: 10.1182/Blood.V116.21.4630.4630 |
0.442 |
|
| 2010 |
Tombleson R, Ho VQ, Sotomayor EM, Bello CM, Cultrera JL, Pinilla-Ibarz J, Sokol L, Wetzstein GA. Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions Blood. 116: 4370-4370. DOI: 10.1182/Blood.V116.21.4370.4370 |
0.358 |
|
| 2010 |
Corrales-Yepez M, Kharfan-Dabaja MA, Lancet J, List AF, Padron E, Rollison D, Epling-Burnette P, Zhang L, Field T, Pinilla-Ibarz J, Komrokji RS. Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes Blood. 116: 4001-4001. DOI: 10.1182/Blood.V116.21.4001.4001 |
0.327 |
|
| 2010 |
Padron E, Komrokji RS, Lancet JE, List AF, Dessureault S, Antonia S, Ahmed J, Patel S, Powers J, Bai F, Sotomayor EM, Epling-Burnette P, Pinilla-Ibarz J. A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS) Blood. 116: 2925-2925. DOI: 10.1182/Blood.V116.21.2925.2925 |
0.43 |
|
| 2010 |
Cheng F, Wang H, Woan K, Rock-Klotz J, Wang Z, Merino O, Gill A, Marante D, Vazquez L, Seto E, Pinilla-Ibarz J, Sotomayor EM, Villagra A. Targeting Histone Deacetylase 6 (HDAC6) as a Novel Approach to Overcome T-Cell Anergy. Blood. 116: 1483-1483. DOI: 10.1182/Blood.V116.21.1483.1483 |
0.361 |
|
| 2010 |
Hartley MA, Zhang L, Bulkeley W, Shah BD, Tinsley S, Pinilla-Ibarz J. Hematopathologic Evaluation of Myelodysplastic Features of Patients with CP-CML on Therapy with Clonal Cytogenetic Abnormalities In Ph Negative Clones Blood. 116: 1224-1224. DOI: 10.1182/Blood.V116.21.1224.1224 |
0.408 |
|
| 2010 |
Nair RR, Tolentino JH, Argilagos RF, Pinilla-Ibarz J, Hazlehurst LA. Abstract 564: A >50KDa soluble factor from the stroma-derived conditioned media contributes to resistance towards BCR-ABL inhibitors in CML via the JAK-STAT3 pathway Cancer Research. 70: 564-564. DOI: 10.1158/1538-7445.Am10-564 |
0.358 |
|
| 2010 |
Dubovsky JA, Powers JJ, Gao Y, Pinilla-Ibarz JA, Sotomayor EM. Abstract 4771: Molecular, epigenetic, and phenotypic repolarization of human T lymphocytes using 5-aza-2′-deoxycytidine increases CD8 responsiveness and induces Th1 polarity Cancer Research. 70: 4771-4771. DOI: 10.1158/1538-7445.Am10-4771 |
0.674 |
|
| 2010 |
Kharfan-Dabaja M, Perkins J, Cortes R, Brand L, Fernandez H, Ochoa-Bayona J, Field T, Perez L, McIsaac C, Maddox B, Ayala E, Komrokji R, Pinilla-Ibarz J, Sotomayor E, Tomblyn M, et al. A Novel Reduced Toxicity Preparative Regimen For Hematopoietic Cell Allografting Combining Pentostatin (Nipent®) And Targeted Doses Of Intravenous Busulfan (Busulfex®) With Or Without Rituximab (PB±R) Using CD4-Guided Immune Suppression: Preliminary Results Of An Ongoing Prospective Trial Biology of Blood and Marrow Transplantation. 16: S281. DOI: 10.1016/J.Bbmt.2009.12.376 |
0.351 |
|
| 2009 |
Pinilla-Ibarz J, Quintas-Cardama A. New agents in the treatment of chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : Jnccn. 7: 1028-37. PMID 19878642 DOI: 10.6004/jnccn.2009.0066 |
0.318 |
|
| 2009 |
Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3406-15. PMID 19401350 DOI: 10.1182/Blood.V112.11.4207.4207 |
0.684 |
|
| 2009 |
Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 16: 141-52. PMID 19337200 DOI: 10.1177/107327480901600206 |
0.662 |
|
| 2009 |
Pinilla-Ibarz J. A new era in the treatment of chronic myeloid leukemia. Cancer Control : Journal of the Moffitt Cancer Center. 16: 96-7. PMID 19337195 DOI: 10.1177/107327480901600201 |
0.319 |
|
| 2009 |
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23: 1398-405. PMID 19295545 DOI: 10.1038/Leu.2009.46 |
0.468 |
|
| 2009 |
Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunology. 10: 92-100. PMID 19011628 DOI: 10.1038/Ni.1673 |
0.389 |
|
| 2009 |
Komrokji RS, Kharfan-Dabaja MA, Price SL, Wetzstein GA, List AF, Fernandez HF, George TJ, Pinilla-Ibarz J, Ho VQ, Lancet JE. Albumin Is a Prognostic Factor for Response and Overall Survival in Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood. 114: 4685-4685. DOI: 10.1182/Blood.V114.22.4685.4685 |
0.367 |
|
| 2009 |
Veliz M, Moscinski LC, Zhang L, Sotomayor EM, Pinilla-Ibarz J. Lymphoplasmacytic Differentiation Associated with Lenalidomide Therapy in Patients with Chronic Lymphocytic Leukemia. Blood. 114: 4412-4412. DOI: 10.1182/Blood.V114.22.4412.4412 |
0.466 |
|
| 2009 |
Kantarjian HM, Jabbour E, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Wang J, Woodman RC, Baccarani M, le Coutre PD, Cortes J. Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data. Blood. 114: 3298-3298. DOI: 10.1182/Blood.V114.22.3298.3298 |
0.402 |
|
| 2009 |
Veliz M, Santana R, Lancet JE, Komrokji RS, Kharfan-Dabaja MA, Powers JJ, Dubovsky JA, Tinsley S, Deaver D, Sotomayor EM, Pinilla-Ibarz J. Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis. Blood. 114: 2376-2376. DOI: 10.1182/Blood.V114.22.2376.2376 |
0.703 |
|
| 2009 |
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D, Shou Y, Gallagher NJ, et al. Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. Blood. 114: 1129-1129. DOI: 10.1182/Blood.V114.22.1129.1129 |
0.402 |
|
| 2009 |
Price SL, George TJ, Wetzstein GA, Lancet JE, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?. Blood. 114: 1022-1022. DOI: 10.1182/Blood.V114.22.1022.1022 |
0.392 |
|
| 2009 |
Pinilla-Ibarz J. Ten Best Readings Relating to Chronic Myeloid Leukemia (CML) Cancer Control. 16: 188-189. DOI: 10.1177/107327480901600212 |
0.305 |
|
| 2008 |
Pinilla-Ibarz J, Kantarjian HM, Cortes JE, le Coutre P, Nagler A, Hochhaus A, Jones D, Kimura S, Giampalmi J, Gleich L, Ottmann OG. A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7018. PMID 27950020 DOI: 10.1200/Jco.2008.26.15_Suppl.7018 |
0.331 |
|
| 2008 |
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics. 7: 3169-75. PMID 18852120 DOI: 10.1158/1535-7163.Mct-08-0314 |
0.335 |
|
| 2008 |
Pinilla-Ibarz J, Bello C. Modern approaches to treating chronic myelogenous leukemia. Current Oncology Reports. 10: 365-71. PMID 18706263 DOI: 10.1007/S11912-008-0057-0 |
0.389 |
|
| 2008 |
Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer. 113: 897-906. PMID 18618518 DOI: 10.1002/cncr.23671 |
0.309 |
|
| 2008 |
Pidala J, Pinilla-Ibarz J, Cualing HD. A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). Cancer Genetics and Cytogenetics. 182: 46-9. PMID 18328951 DOI: 10.1016/J.Cancergencyto.2007.12.009 |
0.312 |
|
| 2008 |
Kharfan-Dabaja MA, Tate C, Perkins J, Field T, Fernandez HF, Alsina M, Ayala E, Raychaudhuri J, Perez L, Ochoa-Bayona JL, Brand L, Pinilla-Ibarz J, Sotomayor E, Sullivan D, Anasetti C. Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies Blood. 112: 4323-4323. DOI: 10.1182/Blood.V112.11.4323.4323 |
0.357 |
|
| 2007 |
May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4547-55. PMID 17671141 DOI: 10.1158/1078-0432.Ccr-07-0708 |
0.34 |
|
| 2006 |
Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein Leukemia. 20: 2025-2033. PMID 16990779 DOI: 10.1038/Sj.Leu.2404380 |
0.311 |
|
| 2006 |
Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 107: 2045-51. PMID 16269613 DOI: 10.1182/Blood-2005-07-2828 |
0.366 |
|
| 2005 |
Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner IM, Pamer EG, van den Brink MR, Scheinberg DA. Remodeling Specific Immunity by Use of MHC-Tetramers Distinguishes Graft-Versus-Tumor Activity from Graft-Versus-Host-Disease. Blood. 106: 1300-1300. DOI: 10.1182/Blood.V106.11.1300.1300 |
0.389 |
|
| 2004 |
Moldenhauer A, Frank RC, Pinilla-Ibarz J, Holland G, Boccuni P, Scheinberg DA, Salama A, Seeger K, Moore MA, Nimer SD. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Journal of Leukocyte Biology. 76: 623-33. PMID 15197237 DOI: 10.1189/Jlb.1103581 |
0.388 |
|
| 2004 |
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 103: 1037-42. PMID 14504104 DOI: 10.1182/Blood-2003-03-0954 |
0.376 |
|
| 2004 |
Kappel B, Eng J, Pinilla-Ibarz J, van den Brink M, Scheinberg D. Selective depletion of T cell clones responsible for GVHD in a murine model Biology of Blood and Marrow Transplantation. 10: 20-21. DOI: 10.1016/J.Bbmt.2003.12.076 |
0.333 |
|
| 2003 |
Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Seminars in Hematology. 40: 87-96. PMID 12563615 DOI: 10.1053/shem.2003.50007 |
0.312 |
|
| 2003 |
Schwartz J, Pinilla-Ibarz J, Yuan RR, Scheinberg DA. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia Seminars in Hematology. 40: 87-96. DOI: 10.1016/S0037-1963(03)70046-8 |
0.421 |
|
| 2002 |
Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 99: 3748-55. PMID 11986232 DOI: 10.1182/Blood.V99.10.3748 |
0.329 |
|
| 2000 |
Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer Blood Reviews. 14: 111-120. PMID 11012250 DOI: 10.1054/Blre.2000.0127 |
0.426 |
|
| 2000 |
Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA. Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches Current Opinion in Hematology. 7: 247-254. PMID 10882181 DOI: 10.1097/00062752-200007000-00008 |
0.389 |
|
| 2000 |
Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses Blood. 95: 1781-1787. DOI: 10.1182/Blood.V95.5.1781.005K46_1781_1787 |
0.362 |
|
| Show low-probability matches. |